Targeting the vascular endothelial growth factor in hematologic malignancies

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Angiogenic growth factors, particularly vascular endothelial growth factor (VEGF), are increasingly implicated in hematolymphoid malignancies beyond solid tumors.
• Bone marrow microvessel density and angiogenesis correlate with prognosis and disease burden in these cancers.
• VEGF and its receptors are expressed in various leukemic and lymphoma cells, influencing their growth and survival.

Purpose of the Study:

• To review the angiogenesis-independent roles of VEGF in leukemic and lymphoma cell survival and proliferation.
• To explore therapeutic strategies targeting VEGF signaling in hematologic malignancies.

Main Methods:

• Literature review focusing on the molecular mechanisms of VEGF in hematologic cancers.
• Analysis of studies investigating the expression of VEGF and its receptors in leukemic and lymphoma cells.
• Examination of preclinical and clinical data on anti-VEGF/VEGF-receptor therapies.

Main Results:

• VEGF/VEGF-receptor interactions mediate autocrine and paracrine signaling, promoting leukemic cell proliferation, migration, and survival.
• VEGF exhibits angiogenesis-independent effects on malignant cell behavior.
• Inhibition of VEGF signaling presents a potential therapeutic avenue.

Conclusions:

• VEGF plays a critical role in the pathogenesis of hematologic malignancies through both angiogenesis-dependent and -independent mechanisms.
• Targeting VEGF signaling pathways offers a promising therapeutic strategy for treating leukemias and lymphomas.
• Further research into anti-VEGF therapies is warranted for hematologic diseases.